Who owns BRIDGEBIO PHARMA INC?
- CUSIP Number: 10806xad4
Tip: Access positions for across all investors
Analyze quarterly positions in Bridgebio Pharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Bridgebio Pharma stock
Who bought or sold BRIDGEBIO PHARMA INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Linden Advisors | 240M | $266M | 0% | Jun 2026 |
|
| Ing Investment Management | 159M | $177M | -5% | Jun 2026 |
|
| Context Capital Management | 57M | $63M | -20% | Jun 2026 |
|
| MacKay Shields | 33M | $37M | 0% | Jun 2026 |
|
| Wolverine Asset Management | 24M | $27M | -13% | Jun 2026 |
|
| Lord, Abbett & Co | 23M | $26M | -20% | Jun 2026 |
|
| Silverback Asset Management | 20M | $22M | -11% | Jun 2026 |
|
| Laurion Capital Management | 19M | $21M | 0% | Jun 2026 |
|
| BlackRock | 15M | $17M | 27% | Jun 2026 |
|
| State Street Corporation | 15M | $17M | -4% | Mar 2026 |
|
| Advent Capital Management | 15M | $16M | -23% | Jun 2026 |
|
| Agf Management | 9.5M | $11M | 280% | Jun 2026 |
|
| FMR | 8.6M | $9.5M | -1% | Jun 2026 |
|
| Lazard Asset Management | 7.1M | $79k | 11% | Jun 2026 |
|
| Wells Fargo & Company | 6.5M | $7.2M | -27% | Jun 2026 |
|
| Goldman Sachs Group | 6.5M | $7.2M | 45% | Jun 2026 |
|
| SSI Investment Management | 6.1M | $6.7M | 0% | Jun 2026 |
|
| Bnp Paribas Arbitrage, Snc | 5.1M | $5.7M | 40% | Jun 2026 |
|
| Calamos Advisors | 5.0M | $5.6M | 0% | Jun 2026 |
|
| OZ Management | 5.0M | $5.6M | -29% | Jun 2026 |
|
| Toronto-Dominion Bank | 4.6M | $5.1M | 26% | Jun 2026 |
|
| Jpmorgan Chase & Co | 3.7M | $4.1M | 100% | Jun 2026 |
|
| RWC Asset Management | 3.1M | $3.5M | -5% | Jun 2026 |
|
| Royal Bank of Canada | 3.1M | $3.4M | 589% | Jun 2026 |
|
| Bnp Paribas Investment Partners | 2.5M | $2.8M | 0% | Jun 2026 |
|
| Citigroup | 2.1M | $2.4M | 100% | Mar 2026 |
|
| Nomura Asset Management International | 1.8M | $2.0M | 100% | Jun 2026 |
|
| Bank of New York Mellon | 1.0M | $1.1M | 0% | Jun 2026 |
|
| Barclays | 727k | $808k | 100% | Jun 2026 |
|
| Universal- Beteiligungs- und Servicegesellschaft mbH | 600k | $675k | 0% | Jun 2026 |
|
| Deutsche Bank Aktiengesellschaft | 446k | $494k | 49% | Jun 2026 |
|
| Sei Investments | 377k | $417k | 0% | Jun 2026 |
|
| UBS Group | 309k | $342k | -6% | Jun 2026 |
|
| Ubs Global Asset Management Americas | 275k | $304k | 100% | Jun 2026 |
|
| Virtus Fixed Income Advisers | 167k | $185k | 100% | Jun 2026 |
|
| Oppenheimer Asset Management | 109k | $121k | 4% | Jun 2026 |
|
| CSS | 71k | $79k | 100% | Jun 2026 |
|
| ADAR1 Capital Management | 45k | $4.9M | 0% | Jun 2026 |
|
| Virtus ETF Advisers | 38k | $42k | 0% | Jun 2026 |
|
| Stephens | 32k | $35k | -3% | Jun 2026 |
|
Who sold out of Bridgebio Pharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Jane Street | Mar 2026 | 2.8M | $3.1M |
| Morgan Stanley | Dec 2025 | 1.5M | $1.7M |
| Leucadia National Corporation | Mar 2026 | 1.5M | $1.7M |
| Shenkman Capital Management | Mar 2026 | 376k | $423M |
| Wellesley Investment Advisors | Mar 2026 | 210k | $237M |